【摘要】 目的:探讨ER,PR和p16联合免疫组化染色在子宫内膜腺癌和宫颈腺癌鉴别诊断中的价值。方法:采用免疫组化SP法染色,观察ER,PR,p16在子宫内膜腺癌和宫颈腺癌中的表达情况。结果:子宫内膜腺癌中ER,PR和p16的阳性率分别为85.29%、76.47%、23.52%;宫颈腺癌为33.33%、42.86%、80.95%,子宫内膜腺癌ER,PR的阳性率明显高于宫颈腺癌,宫颈腺癌p16的阳性率明显高于子宫内膜腺癌。在子宫内膜腺癌和宫颈腺癌中3种标记差异均有显著性(ER:χ2=20.78 P<0.005;PR:χ2=8.32 P<0.01;p16:χ2=17.24 P<0.005)。结论:ER,PR,p16联合检测对鉴别子宫内膜腺癌和宫颈腺癌有一定实用价值。更多还原

【Abstract】 Objective: To study the clinical significance of tumor markers combined assay in the differential diagnosis of endometrial and cervical adenocarcinomas.Methods: Immunohistochemical SP method was used to detect expressions of ER,PR and p16 in paraffin-embedded tissues in 34 cases of endometrial adenocarcinomas,and 21 cases of cervical adenocarcinomas.Results: Positive rates of ER,PR,p16 in endometrial adenocarcinomas were 85.29%,76.47%,and 23.52% respectively;those in cervical adenocarcinomas were 33.33%,42.86% and 80.95% respectively.The positive rates of ER and PR in endometrial adenocarcinomas were higher significantly than those in cervical adenocarcinomas(P<0.005) and the positive rate of p16 in cervical adencarcinomas was significantly higher than that in endometrial adenocarcinomas(P<0.005).Conclusion: The combined assays of ER,PR and P16 may have significantly clinical value in the differential diagnosis of primary endometrial and cervical adenocarcinomas.更多还原